Healthcare Jan 12, 2022 09:28 AM (GMT+8) · EqualOcean
Yiouda health learned on the 12th that Shanghai Zhenge Biotechnology Co., Ltd. ("Zhenge biotechnology") announced the completion of a round C financing of US $100 million, led by Goldman Sachs asset management and Sofina, followed by Novo holdings A / s, Qiming venture capital, IDG capital, ZhouLing capital, Junxin capital and Tongchuang Weiye. The funds raised in round C will be used to further strengthen the global R & D center of Zhenge biology and expand the production capacity in line with drug production quality management practices (GMP) to meet the needs of customers at home and abroad. So far, Zhenge biology has provided services to more than 100 biopharmaceutical and biotechnology enterprise customers, and completed more than 150 projects, including cell line development, new drug clinical trial (ind) application and large-scale clinical stage production contracts.